Introducing Medisca Nutraceuticals

Download in electronic PDF format for $25



Search the Complete Journal Archives

Compatibility and Stability of Palonosetron Hydrochloride and Propofol During Simulated Y-Site Administration

Author(s):  Trissel Lawrence A, Trusley Craig, Kupiec Thomas C, Ben Michel

Issue:  Jan/Feb 2009 - Compounding for Pediatrics
View All Articles in Issue

Abstract:  Palonosetron hydrochloride is a longer-acting, selective 5-HT3 receptor antagonist that has been approved for prevention of chemotherapy-induced nausea and vomiting and is being evaluated for prevention of postoperative nausea and vomiting. The objective of this study was to evaluate the physical and chemical stability of palonosetron hydrochloride 50 mcg/mL when mixed with undiluted propofol 1% during simulated Y-site administration. Duplicate samples of this mixture were tested. Samples were stored and evaluated for up to 4 hours at room temperature. Physical stability was assessed by visual inspection. Chemical stability was assessed by high-performance liquid chromatographic analysis. All of the admixtures were opaque white when viewed in normal fl uorescent room light and when viewed with a Tyndall beam. After centrifugation, no evidence of precipitation was found. The drug concentrations were essentially unchanged in all of the samples throughout the study. Palonosetron hydrochloride is physically and c

Related Keywords: stability, compatibility, propofol, chemotherapy, surgery, Lawrence A. Trissel, BS, RPh, FASHP, Craig Trusley, PharmD, MS, Thomas C. Kupiec, PhD, Michel Ben, MS, palonosetron hydrochloride, selective 5-HT3 receptor antagonist, nausea, vomiting, prevention, parenteral administration, intravenous infusion, drug admixtures

Related Categories: GASTROENTEROLOGY, PARENTERALS, PEER-REVIEWED, STABILITIES, COMPATIBILITIES

Printer-Friendly Version

Related Articles from IJPC
Title (Click for Abstract / Details) Author Issue Page View/Buy
Compatibility and Stability of Palonosetron Hydrochloride and Propofol During Simulated Y-Site Administration Trissel Lawrence A, Trusley Craig, Kupiec Thomas C, Ben Michel Jan/Feb 2009 78-80 Buy
Compatibility and Stability of Palonosetron Hydrochloride with Gentamicin, Metronidazole, or Vancomycin During Simulated Y-Site Administration Kupiec Thomas C, Ben Michel, Trusley Craig, Trissel Lawrence A Mar/Apr 2008 170-173 Buy
Compatibility and Stability of Palonosetron Hydrochloride with Four Neuromuscular Blocking Agents During Simulated Y-Site Administration Trusley Craig, Ben Michel, Kupiec Thomas C, Trissel Lawrence A Mar/Apr 2008 156-160 Buy
Compatibility and Stability of Palonosetron Hydrochloride with Lactated Ringer's, Hetastarch in Lactated Electrolyte, and Mannitol Injections During Simulated Y-Site Administration Ben Michel, Kupiec Thomas C, Trusley Craig, Trissel Lawrence A Sep/Oct 2008 460-462 Buy
Palonosetron Hydrochloride Compatibility and Stability with Three Beta-Lactam Antibiotics During Simulated Y-Site Administration Ben Michel, Trusley Craig, Kupiec Thomas C, Trissel Lawrence A Nov/Dec 2007 520-524 Buy
Physical and Chemical Stability of Palonosetron Hydrochloride with Glycopyrrolate and Neostigmine During Simulated Y-Site Administration Ben Michel, Trusley Craig, Kupiec Thomas C, Trissel Lawrence A Jul/Aug 2008 368-371 Buy
Compatibility of Micafungin Injection with Other Drugs During Simulated Y-Site Co-administration Trusley Craig, Kupiec Thomas C, Trissel Lawrence A May/Jun 2006 230-233 Buy
Physical and Chemical Stability of Palonosetron Hydrochloride with Topotecan Hydrochloride and Irinotecan Hydrochloride during Simulated Y-Site Administration Trissel Lawrence A, Xu Quanyun A May/Jun 2005 238-241 Buy
Physical and Chemical Stability of Palonosetron Hydrochloride with Lorazepam and Midazolam Hydrochloride during Simulated Y-Site Administration Trissel Lawrence A, Xu Quanyun A May/Jun 2005 235-237 Buy
Compatibility of Caspofungin Acetate Injection with Other Drugs During Simulated Y-Site Coadministration Chan Pak, Heatherly Kathy, Kupiec Thomas C, Trissel Lawrence A May/Jun 2008 276-278 Buy